What is tirzepatide, how well does it work, and how does it compare to semaglutide?

The short answer

Tirzepatide is a once-weekly dual GIP/GLP-1 receptor agonist (Mounjaro for diabetes, Zepbound for obesity) that delivers the largest average weight loss of any approved drug to date — around 20%+ at the top dose — and beat semaglutide head-to-head. The trade-off is GI side effects, a careful titration, and class cautions that apply in full.

Evidence tier: 1–2 for the core efficacy and head-to-head data (large randomized trials: SURMOUNT-1, SURMOUNT-5, SURPASS-2). Safety framing is the established class profile. This is education, not medical advice — tirzepatide is a prescription medicine and dosing belongs with your clinician.

The key points:

• Dual mechanism — it hits both GIP and GLP-1 receptors, unlike single-agonist semaglutide
• Best-in-class weight loss — ~20%+ average at 15 mg, and superior to semaglutide head-to-head
• GI side effects dominate — nausea, diarrhea, constipation, managed by slow titration
• Class cautions apply — thyroid C-cell warning, pancreatitis/gallbladder signals, lean-mass loss, hard pregnancy stop

This is a deep dive within our GLP-1 complete guide; compare it directly with our semaglutide deep dive.

What tirzepatide actually is

Evidence tier: 2 — established pharmacology.

Tirzepatide is the first approved "twincretin" — a single molecule that activates two incretin receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Semaglutide and the older drugs in this space are single GLP-1 agonists; tirzepatide adds the GIP arm, and that dual action is the leading explanation for why it tends to outperform on both glucose control and weight. It's dosed once weekly by subcutaneous injection and sold under two brand names for two indications: Mounjaro for type 2 diabetes and Zepbound for obesity, both from Eli Lilly.

Mechanistically, the GLP-1 component slows gastric emptying, increases satiety, and improves glucose-dependent insulin secretion, while the GIP component appears to add complementary effects on insulin sensitivity and appetite regulation. The honest caveat is that GIP biology is still being worked out — there's even debate about whether agonism or antagonism of GIP is the active ingredient — but the clinical results are not in dispute. For the structured entity summary and dosing card, see our tirzepatide peptide page.

How much weight do people actually lose?

Evidence tier: 1 — pivotal randomized trial.

This is tirzepatide's headline. In SURMOUNT-1, the pivotal 72-week obesity trial, tirzepatide produced a mean weight reduction of roughly 15% at 5 mg, ~19–20% at 10 mg, and around 20%+ at 15 mg, versus about 3% on placebo (Jastreboff 2022). Those are the largest average reductions seen with any approved anti-obesity medication, approaching what was once only achievable with bariatric surgery for a meaningful share of participants. A large fraction of people on the top dose lost 25% or more of their body weight.

Two honest qualifiers. First, these are averages from a trial with structured support; real-world results vary, and adherence and lifestyle still matter. Second, the weight is lost over many months of gradual titration, not quickly — the trajectory is slow and steady, which is actually a feature for tolerability. The practical expectation to set is "substantial loss over a year," not a rapid drop. The same plateau-and-maintenance dynamics covered in our GLP-1 community insights apply here too.

Is tirzepatide better than semaglutide?

Evidence tier: 1 — direct head-to-head randomized trials.

For once, this isn't a matter of indirect comparison — there are direct head-to-head trials, and tirzepatide won both. In SURMOUNT-5, a head-to-head obesity trial, tirzepatide produced significantly greater weight loss than semaglutide (roughly 20% vs 14%) over 72 weeks, along with greater improvements in cardiometabolic markers (Aronne 2025). In SURPASS-2, the diabetes head-to-head, tirzepatide achieved superior HbA1c reduction and greater weight loss than semaglutide (Frías 2021).

So on the narrow question of efficacy, tirzepatide is the stronger drug. But "better" isn't only efficacy. Semaglutide has the larger cardiovascular-outcomes evidence base so far (the SELECT trial), longer real-world track record, and an oral option — all things tirzepatide is still building. The right framing is that tirzepatide is the efficacy leader while semaglutide is the more established all-rounder, and the choice depends on the goal, tolerability, access, and what evidence matters most for a given person. We lay out the full comparison in the semaglutide deep dive.

What are the side effects?

Evidence tier: 1–2 — consistent across the trial program.

The side-effect profile is dominated by the gut. Nausea, diarrhea, constipation, vomiting, and reduced appetite are the common complaints, most pronounced during dose escalation and usually easing as the body adapts. They're the main reason the drug is titrated up slowly over months rather than started at an effective dose — rushing the titration reliably produces worse GI effects and more dropouts. For the practical management playbook (timing, diet, hydration, when to hold a dose), our GLP-1 side-effects guide applies directly to tirzepatide.

Beyond the GI effects, the class-level cautions apply in full: a boxed warning regarding thyroid C-cell tumors (contraindicated with a personal/family history of medullary thyroid carcinoma or MEN 2), signals for pancreatitis and gallbladder disease, and the risk of dehydration-related kidney issues if vomiting and diarrhea are severe. None of these is common, but they're the reasons tirzepatide is a prescribed-and-monitored medicine rather than something to self-source. The lean-mass and pregnancy issues below round out the picture.

The lean-mass and "what happens when you stop" questions

Evidence tier: 2 — consistent with the GLP-1 class.

Two issues deserve specific attention because they shape long-term outcomes. First, lean mass: large, rapid weight loss includes some muscle, not just fat, and that matters for metabolism, strength, and healthy aging. The mitigation is well established and worth doing from the start — adequate protein and resistance training preserve more lean mass through the loss. This is especially important for older adults and anyone whose baseline muscle is already low.

Second, discontinuation: like the rest of the class, tirzepatide manages weight while it's taken, and stopping commonly leads to regain unless other changes hold. This isn't a moral failing or a sign the drug "didn't work" — it reflects that obesity is a chronic condition and the drug treats it rather than curing it. The practical implication is to think of tirzepatide as a long-term or carefully-tapered intervention with a maintenance plan, not a short course. For anyone who could become pregnant, that long-term framing also has to accommodate the hard pre-conception stop covered next.

What about women, fertility, and pregnancy?

Evidence tier: 2 — reproductive considerations grounded in class data.

Tirzepatide carries the same reproductive considerations as the rest of the GLP-1 class, and they're significant enough to flag here. It must be stopped before a planned pregnancy with adequate washout, and pregnancy or the intention to conceive is itself a reason to stop. There's also a specific contraception note: tirzepatide can reduce the effectiveness of oral contraceptives around initiation and dose escalation, so the label advises a backup non-oral method or switching during that window — a detail that's easy to miss and genuinely matters.

For women using tirzepatide for PCOS or weight, the same fertility paradox applies that we cover in GLP-1s for women: PCOS and fertility: the weight loss can restore ovulation and lead to unplanned pregnancy. So contraception is an active decision, not an assumption. This reproductive layer is one of the clearest examples of why drug-specific, woman-specific detail matters rather than generic "it's a weight-loss shot" framing.

So who is tirzepatide for?

Evidence tier: 2–3 — synthesis into practical guidance.

Pulling it together: tirzepatide is the efficacy front-runner, so it's a strong consideration for someone whose primary goal is maximal weight loss or robust glucose control and who can access it and tolerate the titration. The GI side effects are the main barrier, and they're manageable with slow escalation and the standard mitigations. The class cautions — thyroid history, pancreatitis/gallbladder risk, lean-mass preservation, and the pregnancy rules — define who should be careful or avoid it, which is exactly why it's a clinician-managed prescription rather than a self-sourced peptide.

The honest comparison is that tirzepatide edges out semaglutide on efficacy while semaglutide leads on cardiovascular-outcome evidence and track record, so the decision is individual. Whatever the choice, the drug works best embedded in a plan: protein and resistance training to protect muscle, a maintenance strategy for the long term, and a clinician managing the titration and monitoring.

Limitations

This is educational content, not medical advice.

• Tirzepatide is a prescription medicine — dosing, titration, and monitoring belong with a clinician.
• Trial averages aren't individual guarantees — real-world results vary with adherence and lifestyle.
• The cardiovascular-outcomes evidence is still maturing relative to semaglutide's SELECT data.
• Class cautions apply in full — thyroid C-cell warning, pancreatitis/gallbladder, lean-mass loss.
• Pregnancy requires a planned pre-conception stop; oral contraception may be less effective during titration.
• Compounded/gray-market versions add sourcing risk — verify via Finnrick.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Tirzepatide is the current efficacy leader in the GLP-1 space — a dual GIP/GLP-1 agonist delivering around 20%+ average weight loss and beating semaglutide in direct head-to-head trials on both weight and glucose. The cost of that potency is a GI-heavy side-effect profile that demands slow titration, plus the full set of class cautions: thyroid C-cell warning, pancreatitis and gallbladder signals, lean-mass loss, and a hard pregnancy stop. It's the strongest choice for maximal weight or glucose goals, while semaglutide still leads on cardiovascular-outcome evidence — making the decision an individual, clinician-guided one.

Related on this site

• GLP-1 complete guide (2026)
• Semaglutide deep dive (2026)
• GLP-1 side effects and how to manage them
• GLP-1s for women: PCOS, fertility, and cycle effects
• GLP-1 community insights (2026)
• Tirzepatide peptide page
• Our evidence-tier framework

References

• Jastreboff AM, Aronne LJ, Ahmad NN, et al. 2022. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 387(3):205-216. PMID 35658024 — pivotal obesity efficacy.
• Aronne LJ, et al. 2025. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. PMID 40353578 — head-to-head obesity trial.
• Frías JP, Davies MJ, Rosenstock J, et al. 2021. Tirzepatide versus semaglutide once weekly in type 2 diabetes (SURPASS-2). N Engl J Med. 385(6):503-515. PMID 34170647 — head-to-head diabetes trial.
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. 2023. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 389(24):2221-2232. PMID 37952131 — the comparator's CV-outcome evidence.